202 related articles for article (PubMed ID: 19022943)
1. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.
Bakken GV; Rudberg I; Christensen H; Molden E; Refsum H; Hermann M
Drug Metab Dispos; 2009 Feb; 37(2):254-8. PubMed ID: 19022943
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
3. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans.
Hirota N; Ito K; Iwatsubo T; Green CE; Tyson CA; Shimada N; Suzuki H; Sugiyama Y
Biopharm Drug Dispos; 2001 Mar; 22(2):53-71. PubMed ID: 11745908
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions.
Hasselstrøm J; Linnet K
Drug Metabol Drug Interact; 2006; 21(3-4):187-211. PubMed ID: 16841513
[TBL] [Abstract][Full Text] [Related]
5. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism.
Huang W; Lin YS; McConn DJ; Calamia JC; Totah RA; Isoherranen N; Glodowski M; Thummel KE
Drug Metab Dispos; 2004 Dec; 32(12):1434-45. PubMed ID: 15383492
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients.
Bakken GV; Rudberg I; Molden E; Refsum H; Hermann M
Ther Drug Monit; 2011 Apr; 33(2):222-6. PubMed ID: 21383647
[TBL] [Abstract][Full Text] [Related]
7. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
8. The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.
Topletz AR; Dennison JB; Barbuch RJ; Hadden CE; Hall SD; Renbarger JL
Drug Metab Dispos; 2013 Sep; 41(9):1651-61. PubMed ID: 23780963
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.
Grimm SW; Richtand NM; Winter HR; Stams KR; Reele SB
Br J Clin Pharmacol; 2006 Jan; 61(1):58-69. PubMed ID: 16390352
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
12. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Klees TM; Sheffels P; Thummel KE; Kharasch ED
Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities.
Lee SJ; Goldstein JA
Drug Metab Pharmacokinet; 2012; 27(6):663-7. PubMed ID: 22785258
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
16. Territrems B and C metabolism in human liver microsomes: major role of CYP3A4 and CYP3A5.
Peng FC; Chang CC; Yang CY; Edwards RJ; Doehmer J
Toxicology; 2006 Feb; 218(2-3):172-85. PubMed ID: 16337070
[TBL] [Abstract][Full Text] [Related]
17. A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism.
Lin SN; Chang Y; Moody DE; Foltz RL
J Anal Toxicol; 2004 Sep; 28(6):443-8. PubMed ID: 15516294
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole.
Michaud V; Simard C; Turgeon J
Drug Metab Lett; 2010 Apr; 4(2):95-103. PubMed ID: 21281268
[TBL] [Abstract][Full Text] [Related]
19. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
20. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
Barter ZE; Perrett HF; Yeo KR; Allorge D; Lennard MS; Rostami-Hodjegan A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):516-32. PubMed ID: 21104927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
